Searched for
PFIZER PATENT LOSS
From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- Pfizer scraps weight loss pill after liver injury: What it means for the future of obesity drugs?Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...
- Pfizer buys Seagen for $43B, boosts access to cancer drugsThe deal announced Monday will combine Seagen's technology with Pfizer's scale and strength, Pfizer CEO Albert Bourla said in a statement. ...
- Vaccine maker BioNTech says no need to waive patentsUgur Sahin, the chief executive of BioNTech, rejected the U.S.-backed proposal to temporarily lift some intellectual property rights for va...
- Pfizer plans to bring more global drugs to IndiaAlthough the company sells most of its top 20 global products in India, it is looking to bring in a couple of drugs, the patents of which h...
- Sun Pharma posts Rs 1,276 cr loss in Q1 on patent settlementThe company had posted a net profit after taxes and minority interest of Rs 795.55 crore for the corresponding period previous fiscal.
- Ranbaxy struggling to get approvals for Lipitor; stock downShares of Ranbaxy were trading lower in early trade on Wednesday, following reports that the company is still struggling to get approvals f...
- Companies to gain as Big Pharma goes genericFaced with losses once its blockbusters start losing patents, Big Pharma is now devising strategies to counter the impact.
- Pharma MNCs will call the shots soonForeign drugmakers are poised to regain the supremacy they ceded during the 1970s, thanks to their strategy of gobbling up India’s leading ...
- MNCs back in control of 50% of Indian pharma marketAcquisitions to help MNCs control nearly 50% of $9.5-billion domestic retail drug market: Analysts
- Cipla in talks to supply drugs to Germany’s BIBoehringer Ingelheim in talks with Cipla for supply of generic drugs to the $17-bn German coa for two drugs.
- Cipla in talks with global cos for research agreementMumbai-based drugmaker Cipla is in talks with global pharma majors for a drug research and supply agreement, said a top company executive o...
- Pfizer charges Sun with another patent violationA legal battle between Pfizer and Sun Pharmaceutical has escalated.
- Indian pharma players to benefit from generic drugs in USIncreased use of generic drugs helped the US healthcare system save billions of dollars over last decade. 6 mysteries about swine flu | Swi...
- Pfizer's profit falls on costs to end diabetic treatment salesPfizer, the world’s largest drugmaker, said third-quarter profit fell 77% on costs for ending sales of the diabetes treatment Exubera and c...
- Local generic cos eye US windfallIndian generic pharma companies may now find it easier to challenge patents in the US. In another twist in the battle between innovators an...
- Pfizer may cut jobs, rejig biz to tide over crisisPfizer will likely slash staff and accelerate merger and licencing deals as the pressure on it to improve its financial performance intensi...
- Derailed demerger plan leaves GE Shipping at seaThe stock markets were disappointed at GE Shipping’s proposed demerger of its offshore business falling through. The scrip closed 1.2% down...
Load More
